Sun Pharma moves up on launching Winlevi cream in US market

01 Nov 2021 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 806.80, up by 12.40 points or 1.56% from its previous closing of Rs. 794.40 on the BSE.

The scrip opened at Rs. 794.00 and has touched a high and low of Rs. 808.60 and Rs. 787.50 respectively. So far 34640 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 850.00 on 18-Oct-2021 and a 52 week low of Rs. 455.90 on 30-Oct-2020.

Last one week high and low of the scrip stood at Rs. 838.40 and Rs. 779.00 respectively. The current market cap of the company is Rs. 193482.37 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 33.80% and 11.72% respectively.

Sun Pharmaceutical Industries has launched Winlevi cream in US market. Winlevi cream used for the treatment of acne vulgaris in patients 12 years and older. A first-in-class topical androgen receptor inhibitor, Winlevi was approved by the US Food and Drug Administration (USFDA) in August 2020. Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years.

The US launch of Winlevi enhances Sun Pharma's specialty product portfolio and reflects commitment to meeting patients needs by providing innovative dermatology medicines.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.